Relationship between Homocysteine Metabolism and Ischemic Stroke

Abstract

Abstract:

Hyperhomocysteinemia was believed to be an independent risk factor for ischemic stroke. Based on the background of homocysteine metabolic pathways, with homocysteine and related lipid causing arterial sclerosis as foundmental basis, this article elaborates the relationship between homocysteine and ischemic stroke. As discussed, there is a positive correlation between the level of homocysteine and the severity of ischemic stroke. There are different conclusions whether the lower homocysteine caused by vitamins can or cannot affect the prognosis of stroke. The results of the studies remain controversial on the relationship between hyperhomocysteinemia and various subtypes of ischemic stroke.

Key words: Homocysteine; Hyperhomocysteinemia; Ischemic stroke

摘要：

高同型半胱氨酸血症被认为是卒中的独立危险因素。本文以同型半胱氨酸代谢途径为背景，以同型半胱氨酸及相关血脂致动脉粥样硬化为基础，阐述同型半胱氨酸与缺血性卒中的关系。其中，同型半胱氨酸水平与卒中的严重程度成正比，维生素降低同型半胱氨酸对卒中预后的影响各研究结果不一。高同型半胱氨酸血症与各型缺血性卒中的关系研究结果仍存在争议。

关键词: 同型半胱氨酸; 高同型半胱氨酸血症; 缺血性卒中

LI Qian, ZHOU Yun-Tao, TIAN Wei, et al.. Relationship between Homocysteine Metabolism and Ischemic Stroke[J]. Chinese Journal of Stroke, 2014, 9(09): 797-802.

李茜，周云涛，田卫，等. 型半胱氨酸的代谢与缺血性卒中的相互关系[J]. 中国卒中杂志, 2014, 9(09): 797-802.

References

1 Iso H, Moriyama Y, Sato S, et al. Serum total

homocysteine concentrations and risk of stroke and its

subtypes in Japanese[J]. Circulation, 2004, 109:2766-

2772.

2 Ribo M, Montaner J, Monasterio J, et al. Role

of homocysteine in the acute phase of stroke[J].

Neurologia, 2003, 19:10-14.

3 Delgado -Reye s CV, Wal l ig MA, Ga r row TA.

Immu noh i s t o chemic a l de t e c t ion of b e t a i ne -

homocysteine S-methyltransferase in human, pig, and

rat liver and kidney[J]. Arch Biochem Biophys, 2001,

393:184-186.

4 Mudd SH, Fi n kelst ei n JD, I r reve r re F, et al.

Transsulfuration in mammals. Microassays and tissue

distributions of three enzymes of the pathway[J]. J

Biol Chem, 1965, 240:4382-4392.

5 Jakubowski H. Molecular basis of homocysteine

toxicity in humans[J]. CMLS, 2004, 61:470-487.

6 Ueland PM. Homocysteine species as components of

plasma redox thiol status[J]. Clin Chem, 1995, 41:340-

342.

7 Chwatko G, Jakubowski H. The determination of

homocysteine–thiolactone in human plasma[J]. Anal

Biochem, 2005, 337:271-277.

8 Jakubowski H. Homocysteine is a protein amino acid

in humans. Implications for homocysteine-linked

disease[J]. J Biol Chem, 2002, 277:30425-30428.

9 Jakubowski H. Pathophysiological consequences

of homocysteine excess[J ]. J Nut r, 2006, 136:

1741S-1749S.

10 Molero AE, Altimari CC, Duran DA, et al. Total

pl a sma homo cys t e i ne va lue s among elde r ly

subjects:findings from the Maracaibo Aging Study[J].

Clin Biochem, 2006, 39:1007-1015.

11 Smi t h DEC, Smu ld e r s YM, Blom HJ, e t a l .

Determinants of the essential one-carbon metabolism

metabolites, homocysteine, S-adenosylmethionine,

S-adenosylhomocysteine and folate, in cerebrospinal

fluid[J]. Clin Chem Lab Med, 2012, 50:1641-1647.

12 Kelly PJ, Kistler JP, Shih VE, et al. Inflammation,

homocysteine, and vitamin B6 status after ischemic

stroke[J]. Stroke, 2004, 35:12-15.

13 Refsum H, Nurk E, Smith AD, et al. The Hordaland

Homocysteine Study:a community-based study of

homocysteine, its determinants, and associations with

disease[J]. J Nutr, 2006, 136:1731S-1740S.

14 王健, 金一. 慢性肾功能不全与Hcy水平的关系[J]. 中

国血液流变学杂志, 2007, 2:299-300.

15 Barbieri L, Verdoia M, Schaffer A, et al. Elevated homocysteine and the risk of contrast-induced

nephropathy:A cohort study[J/OL].http://ang.sagepub.

com/content/early/2014/05/14/0003319714533401.

16 Yajnik C, Deshpande SS, Lubree HG, et al. Vitamin

B12 deficiency and hyperhomocysteinemia in rural and

urban Indians[J]. JAPI, 2006, 54:775-782.

17 Jakubowski H. The molecular basis of homocysteine

thiolactone-mediated vascular disease[J]. Clin Chem

Lab Med, 2007, 45:1704-1716.

18 Richard E, Desviat LR, Ugarte M, et al. Oxidative

stress and apoptosis in homocystinuria patients with

genetic remethylation defects[J]. J Cell Biochem, 2013,

114:183-191.

19 Naruszewicz M, Mirkiewicz E, Olszewski AJ, et al.

Thiolation of low-density-lipoprotein by homocysteine

thiolactone causes increased aggregation and altered

interaction with cultured macrophages[J]. Nutr Metab

Cardiovasc Dis, 1994, 4:70-77.

20 Kerkeni M, Tnani M, Chuniaud L, et al. Comparative

study on in vitro effects of homocysteine thiolactone

and homocysteine on HUVEC cells:evidence

for a stronger proapoptotic and proinf lammative

homocysteine thiolactone[J]. Mol Cell Biochem, 2006,

291:119-126.

21 Jakubowski H. Protein homocysteinylation:possible

mechanism underlying pathological consequences

of elevated homocysteine levels[J]. FASEB J, 1999,

13:2277-2283.

22 Jakubowski H. Homocysteine thiolactone:metabolic

origin and protein homocysteinylation in humans[J]. J

Nutr, 2000, 130:377S-381S.

23 Bogdanski P, Pupek-Musialik D, Dytfeld J, et al.

Plasma homocysteine is a determinant of tissue

necrosis factor-α in hypertensive patients[J]. Biomed

Pharmacother, 2008, 62:360-365.

24 Undas A, Bro ek J, Jankowski M, et al. Plasma

homocysteine affects fibrin clot permeability and

resistance to lysis in human subjects[J]. Arterioscler

Thromb Vasc Biol, 2006, 26:1397-1404.

25 Sauls DL, Lockhart E, Warren ME, et al. Modification

of fibrinogen by homocysteine thiolactone increases

resistance to fibrinolysis:a potential mechanism of the

thrombotic tendency in hyperhomocysteinemia[J].

Biochemistry, 2006, 45:2480-2487.

26 Ferretti G, Bacchetti T, Moroni C, et al. Effect of

homocysteinylation of low density lipoproteins on

lipid peroxidation of human endothelial cells[J]. J Cell

Biochem, 2004, 92:351-360.

27 Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart

disease and stroke statistics-2010 update A report

from the American Heart Association[J]. Circulation, 2010, 121:e46-e215.

28 Sacco RL, Anand K, Lee HS, et al. Homocysteine and

the Risk of Ischemic Stroke in a Triethnic Cohort:The

Northern Manhattan Study[J]. Stroke, 2004, 35:2263-

2269.

29 Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine,

MTHFR 677C→T polymorphism, and risk of ischemic

stroke:Results of a meta-analysis[J]. Neurology, 2002,

59:529-536.

30 Kim SJ, Choe YH, Bang OY. Are stroke biomarkers

seeing brain vessels in patients with ischemic stroke?

A C-reactive protein and homocysteine study[J].

Stroke, 2011, 42:1464-1468.

31 梁晨, 高社荣, 梁晓安, 等. 同型半胱氨酸、超敏C-反应

蛋白、纤维蛋白原与脑梗死严重程度及复发的相关性

分析[J]. 中华脑血管病杂志(电子版), 2013, 7:257-260.

32 Yang TH, Chang CY, Hu ML. Various forms of

homocysteine and oxidative status in the plasma

of ischemic-stroke patients as compared to healthy

controls[J]. Clin Biochem, 2004, 37:494-499.

33 Howard VJ, Sides EG, Newman GC, et al. Changes

in plasma homocyst (e) ine in the acute phase after

stroke[J]. Stroke, 2002, 33:473-478.

34 Omr a n i HQ, Sh a n d i z EE , Qa b a i M, e t a l .

Hyperhomocysteinemia, folateo and B12 vitamin in

Iranian patients with acute ischemic stroke[J]. ARYA

Atheroscler, 2011, 7:97-101.

35 张一娜, 王蕤, 武小薇. 血浆同型半胱氨酸水平与老年

脑梗死的关系[J]. 中国老年学杂志, 2007, 3:556-557.

36 刘飞凤. 同型半胱氨酸与动脉粥样硬化性脑血栓形成

患者发病严重程度及远期预后的相关性研究[D]. 上

海:复旦大学, 2012:28-41.

37 Feng C, Bai X, Xu Y, et al. Hyperhomocysteinemia

associates with small vessel disease more closely than

large vessel disease[J]. Int J Med Sci, 2013, 10:408-

412.

38 Khan U, Crossley C, Kalra L, et al. Homocysteine

and its relationship to stroke subtypes in a UK Black

population:The south London ethnicity and stroke

study[J]. Stroke, 2008, 39:2943-2949.

39 Pa r ne t t i L, Ca so V, Sa nt uc c i A, e t a l. Mi ld

hy perhomocysteinemia is a r isk-factor in all

etiological subtypes of stroke[J]. Neurol Sci, 2004,

25:13-17.

40 黄静, 苏平. 血浆同型半胱氨酸与缺血性脑卒中病因

分型及预后的关系研究[J]. 当代医学, 2011, 17:71-73.

41 An SA, Le e HB, Kim Y, e t a l. Pl a sma tot a l

homocysteine level is associated with the pulsatility

index of cerebral arteries in lacunar infarction[J].

Yonsei Med J, 2013, 54:819-824.

42 Held C, Sumner G, Sheridan P, et al. Correlations b e twe e n p l a sma h omo c y s t e i n e a n d f o l a t e

concentrations and carotid atherosclerosis in highrisk

individuals:baseline data from the Homocysteine

and Atherosclerosis Reduction Trial (HART)[J]. Vasc

Med, 2008, 13:245-253.

43 Wu XQ, Ding J, Ge AY, et al. Acute phase homocysteine

related to severity and outcome of atherothrombotic

stroke[J]. Euro J Intern Med, 2013, 24:362-367.

44 Saposnik G, Ray JG, Sheridan P, et al. Homocysteinelowering

therapy and stroke risk, severity, and

disability additional findings from the HOPE 2 trial[J].

Stroke, 2009, 40:1365-1372.

45 武云, 张文慧. 高同型半胱氨酸与脑梗死再发的相关

性研究[J]. 中国临床保健杂志, 2012, 15:262-263.

46 Hankey GJ1, Ford AH, Yi Q, et al. Effect of B

vitamins and lowering homocysteine on cognitive

impairment in patients with previous stroke or

transient ischemic attack:a prespecified secondary

analysis of a randomized, placebo-controlled trial and

meta-analysis[J]. Stroke, 2013, 44:2232-2239.

47 彭小莲. 高同型半胱氨酸血症与脑梗塞TOAST 亚型关

系及治疗研究[J]. 中国医药导刊, 2012, 14:2075-2075.

48 向建军, 许榕仙, 范岩峰, 等. 叶酸, VB6, VB12对血管

细胞粘附分子-1表达影响[J]. 中国公共卫生, 2009, 25:987-988.

49 Lee M, Hong KS, Chang SC, et al. Eff icacy of

homocysteine-lowering therapy with folic acid in

stroke prevention:A meta-analysis[J]. Stroke, 2010,

41:1205-1212.

50 Kelly PJ, Furie KL, Kistler JP, et al. Stroke in

young patients with hyperhomocysteinemia due to

cystathionine beta-synthase deficiency[J]. Neurology,

2003, 60:275-279.

51 洪小琴, 姜慧华. 叶酸和维生素B12、B6对脑卒中患者

血浆同型半胱氨酸、D-二聚体及血脂水平的影响[J].

中国医院药学杂志, 2014, 34:637-639.

52 Selhub J, Jacques PF, Rosenberg IH, et al. Serum

total homocysteine concentrations in the third

Na t iona l He a lt h a nd Nut r it ion Exami na t ion

Survey (1991–1994):population reference ranges

and contribution of vitamin status to high serum

concentrations[J]. Ann Intern Med, 1999, 131:331-339.

53 Toole JF, Malinow MR, Chambless LE, et al.

Lowering homocysteine in patients with ischemic

stroke to prevent recur rent stroke, myocardial

infarction, and death:the Vitamin Intervention for

Stroke Prevention (VISP) randomized controlled

trial[J]. JAMA, 2004, 291:565-575.

[1]	WU Yuqian, ZHANG Yumei, FAN Xiaowei, WANG Anxin, PANG Wenbin. The Efficacy of Kinesthetic Motor Imagery Therapy for Hand Function Rehabilitation of Stroke Patients [J]. Chinese Journal of Stroke, 2022, 17(12): 1366-1371.
[2]	YI Luo, ZHOU Hongyu, QIU Xin, LI Zixiao, WANG Yongjun. DNA Methylation Changes in Atherosclerotic Diseases [J]. Chinese Journal of Stroke, 2022, 17(11): 1163-1170.
[3]	WANG Yubo, LI Zixiao, WANG Yongjun. Progress of the Relationship between Epigenetics and Oxidative Stress after Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(11): 1171-1177.
[4]	CUI Lingyun, QIU Xin, ZHOU Hongyu, LI Zixiao, WANG Yongjun. Progress of the Relationship between DNA Methylation and Type 2 Diabetes [J]. Chinese Journal of Stroke, 2022, 17(11): 1183-1188.
[5]	LIU Guangliang, HAN Kaiyue, SU Wenlong, ZHANG Hao. Effects of Aerobic Cycling Training Intensity on Motor and Cardiopulmonary Fitness in Patients with Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(11): 1203-1208.
[6]	XU Yingxin, ZHANG Shuang, ZHOU Xiaomei, YUAN Jinglin, ZHAO Liuzhuang, YANG Haihua. Correlation of Non-Stenotic Carotid Plaque with Anterior Circulation Embolic Stroke of Undetermined Source [J]. Chinese Journal of Stroke, 2022, 17(11): 1233-1237.
[7]	CHENG Shi, LI Jing, GUO Junping, HU Aixiang, YU Xinwei, HAN Wei, LIANG Ying, ZHANG Yuewei, JI Ruijun. Clinical Characteristics and Risk Factors of Infection in Patients with Acute Stroke during Hospitalization [J]. Chinese Journal of Stroke, 2022, 17(10): 1065-1070.
[8]	XIANG Wei, XU Luyao, ZHANG Manman, WEI Hongchun, LIANG Zhigang. The Frequency and Influencing Factors of Asymmetrical Prominent Veins Sign on Susceptibility-Weighted Imaging in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1097-1102.
[9]	ZHAO Yongrui, LIU Zhanhui. Progress of Diffusion Tensor Imaging in Evaluating Motor Function Prognosis of Patients with Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1114-1119.
[10]	ZHANG Boyu, GUO Yucheng, CUI Yuxia, LI Yingli, LYU Yumei. Seeking Medical Services Decision-Making Status and Relevant Influencing Factors in Patients with Acute Ischemic Stroke: A Review [J]. Chinese Journal of Stroke, 2022, 17(10): 1127-1132.
[11]	WU Tingting, LIU Yafei, YAN Shixi, WU Yiping, ZHANG Zhongbo, ZAHNG Hanfei, FANG Pinping. Application of “Internet Plus” in Emergency Care of Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(10): 1133-1138.
[12]	ZHANG Yige, ZHANG Wan, ZHANG Luyang, WANG Xin, DING Lan, WANG Yuying, PEI Lulu, FANG Hui, XU Yuming, SONG Bo. Association of Artery Occlusion and Recurrent Ischemic Stroke Related with Cerebral Artery Dissection [J]. Chinese Journal of Stroke, 2022, 17(09): 932-936.
[13]	LYU Wei, WANG Anxin, TIAN Xue, ZHANG Xiaoli, XU Yuyuan, MENG Xia. Effect of Xinxuening Capsule on Short-term Functional Outcome in Patients with Ischemic Stroke and High Homocysteine Level [J]. Chinese Journal of Stroke, 2022, 17(09): 972-976.
[14]	ZHANG Xinmiao, PAN Yuesong, XIANG Xianglong, WANG Yongjun, MENG Xia. Early Clinical Pathway Intervention to Improve the Key Performance Indicators of Medical Care for Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(09): 977-984.
[15]	GONG Yutian, LI Jiejie. Advances in the Relationship between IL-6 and Atherosclerotic Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(09): 1022-1026.